Günther Staffler

Dr. Staffler joined AC Immune in 2021 from Affiris following the acquisition of certain assets including the alpha-synuclein (a-syn) active immunotherapy candidate now progressing as ACI-7104.056 through clinical development.   Dr. Staffler worked at Affiris from 2007 as Head of Early Discovery moving into increasingly senior roles to become Chief Technical Officer. Prior to Affiris, he worked at a number of biotech companies in Vienna including Biovertis and Intercell (now Valneva). Dr. Staffler holds a PhD in Immunology from the Medical University of Vienna.